Indian spacetech startups develop microgravity platforms for drug manufacturing
Indian spacetech startups are entering the microgravity manufacturing sector, targeting drug discovery and pharmaceutical production. Companies like Serendipity, AnduraX, and Akashalabdhi are developing platforms to leverage microgravity conditions, which can enable processes difficult to replicate on Earth. Backed by ISRO and private funding, these efforts position India as a potential player in the global microgravity economy.
Editor, Lazyfounder

30 SEC SUMMARY
- Indian spacetech startups are exploring microgravity for drug discovery and pharmaceutical manufacturing, leveraging conditions difficult to replicate on Earth.
- Companies like Serendipity, AnduraX, Akashalabdhi, and Ethereal are developing platforms for in-space manufacturing, targeting high-value products like medicines.
- The global microgravity manufacturing market is projected to expand, with the pharmaceuticals-in-microgravity segment estimated at $768 Mn in 2024 and expected to reach $3 Bn by 2033.
- India’s spacetech ecosystem, supported by ISRO and private initiatives, is positioning itself as a potential player in the global microgravity economy.
TABLE OF CONTENTS
KEY HIGHLIGHTS
- Indian spacetech startups Serendipity, AnduraX, Akashalabdhi, and Ethereal are developing platforms for microgravity-based drug discovery and manufacturing.
- Microgravity enables uniform protein crystals and conditions difficult to replicate on Earth, potentially improving drug development.
- The global pharmaceuticals-in-microgravity market is estimated at $768 Mn in 2024 and expected to reach $3 Bn by 2033.
- ISRO’s planned Bharatiya Antariksh Station and IIT Madras’s ExTeM research group are supporting microgravity experiments and commercialisation.
- Startups are backed by initiatives like IN-SPACe’s Technology Adoption Fund and Riceberg Ventures’ KickSky Space Labs accelerator.
Microgravity’s potential for drug discovery and manufacturing
Microgravity offers conditions that are difficult or impossible to replicate on Earth, such as reduced convection, sedimentation, and buoyancy. This environment allows for the growth of ultra-pure protein crystals, which could advance drug discovery and pharmaceutical manufacturing, according to Inc42.
The International Space Station (ISS) has hosted hundreds of microgravity experiments across biology, medicine, and materials science. Indian astronaut Shubhanshu Shukla recently participated in such research during an 18-day mission aboard the ISS, conducting seven experiments supported by ISRO.
Indian startups entering the microgravity space
Odisha-based startup Serendipity recently flight-tested a prototype satellite designed for pharmaceutical manufacturing under microgravity. The satellite, carrying an autonomous pharmaceutical factory called ‘Alchemy,’ was tested using a high-altitude balloon at the Tata Institute of Fundamental Research in Hyderabad.
Serendipity’s satellite is designed to operate 400-500 km above Earth for weeks or months before re-entering at specific sites for molecule retrieval.
AnduraX, an Andhra Pradesh-based startup founded in 2024, is developing a reusable spaceplane capable of staying in orbit for up to 90 days. It aims to support microgravity research and manufacturing, targeting global pharmaceutical firms for protein crystallisation.
Bengaluru-based Akashalabdhi is building inflatable modular space habitats to serve as infrastructure for the low-Earth-orbit economy. The startup claims microgravity expands the degrees of freedom for manipulating materials, enabling critical manufacturing processes like drug crystallisation.
Ethereal Exploration Guild, which raised $20.5 Mn in Series A funding in January, is developing a reusable rocket with a novel upper stage for in-orbit manufacturing and microgravity experiments.
Market growth and global context
The pharmaceuticals-in-microgravity market is estimated at $768 Mn in 2024 and projected to grow to $3 Bn by 2033, with a 16.7% CAGR, according to Riceberg Ventures. The broader in-space manufacturing market is expected to expand from $1.5 Bn in 2026 to $3.5 Bn by 2030.
Global players like Merck, Redwire, and Varda are already commercialising microgravity manufacturing. For example, Merck has explored reformulating its cancer drug Keytruda using space-grown protein crystals, while Varda collaborates with pharmaceutical firms to develop treatments in orbit.
The UK Space Agency has introduced measures to support in-orbit manufacturing, providing regulatory clarity and pathways for research to reach commercial viability.
Government and academic support
ISRO’s planned Bharatiya Antariksh Station will conduct microgravity experiments across biotechnology, materials science, and human physiology. Its BAS-03 Science Research Module is dedicated to such research.
In January, ISRO invited proposals for microgravity experiments from the Indian research community, signaling support for commercial and scientific applications.
IIT Madras’s ExTeM research group is developing advanced manufacturing technologies for microgravity and collaborating with startups to conduct experiments.
IN-SPACe’s Technology Adoption Fund, a ₹500 crore initiative, has selected its first cohort of startups to help transform early-stage technologies into commercial products.
What this means
Lazyfounder analysis — our interpretation, not reported fact.
For founders and operators, this shift signals a nascent but expanding opportunity in India’s spacetech sector. Microgravity manufacturing is no longer confined to global giants like Merck or Varda—Indian startups are now building the infrastructure to participate in this market. The involvement of ISRO, IIT Madras, and early-stage funding initiatives like IN-SPACe’s Technology Adoption Fund suggests that public and academic institutions are aligning to support commercialisation. This could lower barriers for startups entering the space, particularly those in pharmaceuticals, biotech, and advanced materials. However, the challenge remains in bridging the gap between experimental success and scalable, cost-effective manufacturing. For investors, this space represents a high-risk, high-reward bet on a sector that could redefine drug development and materials science.
Key takeaways
- Microgravity manufacturing could improve drug development by enabling uniform protein crystals and novel biological processes, creating a potential advantage for pharmaceutical and biotech startups.
- Indian startups like Serendipity, AnduraX, and Akashalabdhi are developing infrastructure for in-space manufacturing, positioning India as a potential player in the global microgravity economy.
- Government and academic support, including ISRO’s Bharatiya Antariksh Station and IIT Madras’s ExTeM research group, is accelerating India’s capacity for microgravity research and commercialisation.
- The global pharmaceuticals-in-microgravity market is projected to grow significantly, offering a timeline for Indian startups to move from experimentation to commercial viability.
Sources
- inc42.com · 2026-08-26
India’s Spacetech Ecosystem Looks To Microgravity For Drug Discovery And Manufacturing India’s Spacetech Ecosystem Looks To Microgravity For Drug Discovery And Manufacturing
This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.
About the author
Editor, Lazyfounder
Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.
More stories by Tarun MottliaGet the LazyFounder Brief
Startup, funding and AI news in a five-minute read. Join the early-access list.


